Out-licensing

Method for Inhibiting Angiogenesis using Heparinase

Introduction/Background

Angiogenesis is a fundamental process by which new blood vessels are formed. It is essential in reproduction, development and wound repair. Under these conditions, angiogenesis is highly regulated, so that it is turned on only as necessary, usually for brief periods of days, then completely inhibited. However, many diseases are driven by persistent unregulated angiogenesis. In arthritis, new capillary blood vessels invade the joint and destroy cartilage. In diabetes, new capillaries invade the vitreous, bleed, and cause blindness. Ocular neovascularization is the most common cause of blindness. Tumour growth and metastasis are angiogenesis-dependent. A tumour must continuously stimulate the growth of new capillary blood vessels for the tumour itself to grow.

Aims/Hypothesis

It is an object of the present invention to provide pharmaceutical compositions, and method of use thereof, based on heparinases, for the treatment of diseases involving abnormal angiogenesis.

Research

Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumours, the inhibitor is delivered by means of a biodegradable, polymeric implant.

Conclusion

We have developed pharmaceutical compositions for delivering an effective dose of a heparinase to a desired site.

Relevance/Opportunity

Please enquire quoting reference no. 6061 regarding licensing or codevelopment partnerships.

Preclinical

United States Patent 5,567,417